Drugs / HRS8179
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05690711 | Apr → Dec 2023 | brain edema | Beijing Suncadia Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06732648 | Feb 2025 → Jun 2027 expected | brain edema | Beijing Suncadia Pharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS8179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06732648 ↗ |
| Route | Intravenous | “Intravenous HRS8179” NCT05690711 ↗ |